Free cash flow remains deeply negative, with a peak quarterly outflow of $68.0 million in 2025Q1, illustrating the firm's persistent reliance on external funding to sustain operations.
| Cash from Operations | -134.47M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -207.29% | -128.72% | -25.73% | -27.99% | -246.64% | - |
| Net Income | -145.24M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
| Depreciation & Amortization | -3.03M | -3.03M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.25M | 12.52M | 3.21M | 895K | 424K | 0 |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 4.93M | 0 | 0 | 0 | 0 | 42.96M |
| Working Capital Changes | -1.38M | -3.77M | 7.07M | 12.6M | -7.15M | -3.94M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 4.37M | 2.14M | -751K | 1.38M | 2.8M | 293K |
| Cash from Investing | -104.47M | -71.23M | -192.47M | 0 | 0 | -40M |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | -40M |
| Cash from Financing | 251.18M | 203.06M | 186.58M | 42.86M | 169.72M | 89.87M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 251.47M | 203.13M | 185.95M | 44.92M | 169.71M | 89.87M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -297K | -70K | 631K | -2.06M | 15K | 0 |
| Net Change in Cash | 12.24M | -28.75M | -76.1M | -12.98M | 126.09M | 37.28M |
| Free Cash Flow | -134.47M | -160.59M | -70.21M | -55.84M | -43.63M | -12.59M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -12.44% | -128.72% | -25.73% | -27.99% | -246.64% | - |
| FCF per Share | -2.98 | -4.18 | -2.23 | -1.75 | -1.30 | -9.86 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.97x | 0.87x | 0.81x | 1.18x | 0.24x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
Binary clinical trial failure
As reported in recent financial statements, ArriVent's operating cash flow consistently tracks net losses, with the 2026Q1 period showing a net loss of $43.3 million and an operating cash outflow of $41.9 million, highlighting the company's reliance on external capital to fund ongoing clinical development.
The tight correlation between net loss and operating cash flow suggests that the company lacks significant non-cash expenses to buffer its burn rate. Investors should monitor this alignment, as it indicates that nearly every dollar of accounting loss translates directly into a reduction of the company's cash runway.
Based on the provided quarterly data, ArriVent's free cash flow trajectory remains deeply negative, reaching a peak outflow of $68.0 million in 2025Q1, which underscores the capital-intensive nature of the firm's current Phase 3 clinical trial execution and the absence of any offsetting commercial revenue streams.
The lack of positive free cash flow is expected for a pre-revenue biotech, but the volatility in quarterly outflows suggests that clinical trial milestones drive significant, non-linear cash requirements. This trajectory implies that the company remains entirely dependent on equity markets to sustain its operations until regulatory approval is achieved.
According to historical cash flow filings, ArriVent exhibits erratic working capital movements, such as the $6.0 million inflow in 2023Q4 followed by a $5.9 million outflow in 2025Q1, reflecting the timing of vendor payments and clinical site accruals inherent in a late-stage drug development business model.
These fluctuations in working capital appear to be driven by the timing of clinical trial site payments rather than operational efficiency. Analysts should interpret these swings as temporary liquidity adjustments that do not alter the underlying reality of the company's structural cash burn.
Financial records indicate that stock-based compensation has risen to $3.7 million in 2025Q3, a non-cash expense that effectively obscures the true economic cost of talent retention while simultaneously diluting existing shareholders to preserve the company's dwindling cash reserves for critical R&D activities.
While stock-based compensation is a standard tool for biotech firms to conserve cash, its increasing trend warrants further investigation into the company's long-term incentive alignment. Investors should be aware that this practice shifts the burden of funding operations from the balance sheet to the equity base.
Quick answers to the most common questions about buying AVBP stock.
ArriVent BioPharma, Inc. Common Stock (AVBP) generated $-160.6M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
ArriVent BioPharma, Inc. Common Stock (AVBP) reported negative free cash flow of $160.6M in 2025, indicating capital requirements exceeded cash from operations.
ArriVent BioPharma, Inc. Common Stock (AVBP) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.